阅读说明：本技术 一种具有止咳平喘作用的复方药物组合物及其用途 (Compound pharmaceutical composition with cough and asthma relieving effect and application thereof ) 是由 陈美姿 胡洪波 杜巍 李振华 彭咏波 于 2019-07-10 设计创作，主要内容包括：本发明属于天然药物领域,公开了一种具有止咳平喘作用的复方药物组合物及其用途。该复方药物组合物的活性成分是由非布司他和考来替泊组成,二者优选质量比为1:1～1:10。两者联合用药在镇咳、平喘、祛痰、消肿抗炎及增强免疫力等方面具有良好的活性。(The invention belongs to the field of natural medicines, and discloses a compound medicinal composition with cough and asthma relieving effects and application thereof. The active ingredients of the compound pharmaceutical composition consist of febuxostat and colestipol, and the optimal mass ratio of the febuxostat to the colestipol is 1: 1-1: 10. The combined medicine of the two has good activity in the aspects of relieving cough, relieving asthma, eliminating phlegm, reducing swelling, resisting inflammation, enhancing immunity and the like.)

1. A compound pharmaceutical composition with the effects of relieving cough and asthma is characterized in that: the active ingredients of the compound pharmaceutical composition consist of febuxostat and colestipol.

2. The compound pharmaceutical composition with cough and asthma relieving effect according to claim 1, which is characterized in that: the mass ratio of the febuxostat to the colestipol is 1: 1-1: 10.

3. The compound pharmaceutical composition with cough and asthma relieving effect according to claim 1, which is characterized in that: the mass ratio of the febuxostat to the colestipol is 1: 1-1: 5.

4. The compound pharmaceutical composition with cough and asthma relieving effect according to claim 1, which is characterized in that: the compound pharmaceutical composition also contains a pharmaceutically acceptable carrier.

5. The use of the compound pharmaceutical composition of claim 1 in the preparation of a medicament for relieving cough, relieving asthma, eliminating phlegm, reducing swelling, resisting inflammation, and enhancing immunity.

Technical Field

The invention belongs to the field of natural medicines, and particularly relates to a compound medicinal composition with cough and asthma relieving effects and application thereof.

Background

Chronic bronchitis is caused by exogenous pathogenic factors invading internally and cough due to internal injury, and also caused by improper diet, dysfunction of the spleen in transport and transformation, dampness generation and phlegm accumulation; the disorder of internal organs and the insufficiency of lung-qi and defensive qi cause the erosion of phlegm and obstruction of lung, which are manifested as cough, expectoration, asthma and other symptoms, and the treatment should be done with detoxification, anti-inflammation, cough-relieving, phlegm-resolving and asthma-relieving. Modern medicine considers that chronic bronchitis is caused by infection, physicochemical factors, climate change, allergic factors and the like. The treatment is usually carried out by controlling infection, eliminating phlegm, relieving cough, relieving spasm and asthma, and the treatment of the disease has obvious consistency no matter in traditional medicine or modern medicine.

Febuxostat (FBS for short), namely, non-brezostat, is a 2- [ (3-cyano-4-isobutoxy) phenyl ] -4-methyl-5-thiazolecarboxylic acid chemical name, is a Xanthine Oxidase (XO) inhibitor, is suitable for long-term treatment of hyperuricemia with gout symptoms, and is remarkably and safely used clinically.

Colestipol (CTP) is a cholesterol-lowering drug used for treating type II hyperlipemia. The product is prepared from sodium alkyl benzene sulfonate and tetraethylenepentamine which are used as anion exchange resin, and can block enterohepatic circulation of cholic acid and discharge the cholic acid together with intestinal cholic acid to reduce blood cholesterol; similar to cholestyramine, it is a cholesterol-lowering agent that adsorbs and removes bile acids, and lowers blood cholesterol by about 20%. It is accepted by patients because of no peculiar smell.

Disclosure of Invention

In order to overcome the defects in the prior art, the invention mainly aims to provide a compound pharmaceutical composition with the functions of relieving cough and asthma; the active ingredients of the compound pharmaceutical composition consist of febuxostat and colestipol.

The invention also aims to provide application of the compound medicine composition in preparing medicines for relieving cough, relieving asthma, eliminating phlegm, reducing swelling, resisting inflammation and enhancing immunity.

The purpose of the invention is realized by the following technical scheme:

a compound pharmaceutical composition with cough and asthma relieving effect is provided.

The mass ratio of the febuxostat to the colestipol is preferably 1: 1-1: 10, and more preferably 1: 1-1: 5.

The compound pharmaceutical composition also contains a pharmaceutically acceptable carrier.

The compound pharmaceutical composition is prepared by a conventional preparation process.

The compound medicine composition is used for preparing the medicine for relieving cough, relieving asthma, eliminating phlegm, reducing swelling, resisting inflammation and enhancing immunity.

The compound pharmaceutical composition can be used for the drug treatment of mammals including human beings.

Compared with the prior art, the invention has the following outstanding advantages and beneficial effects: the inventor discovers in earlier stage high-throughput screening research that febuxostat and colestipol are optimally combined in a compatible mode, unexpected effects are obtained through experimental evaluations of mouse ammonia water induced cough effect investigation, guinea pig citric acid induced cough, influence of guinea pig asthma caused by histamine, guinea pig allergic asthma caused by egg protein, rat capillary method sputum excretion, mouse phenol red method phlegm elimination, rat anti-inflammatory experiments, mouse chronic bronchitis, mouse ear swelling caused by xylene, mouse capillary permeability, and non-specific immune function on carbon particle clearance capability in phagocytic blood flow of a normal mouse reticuloendothelial system (RES), normal mouse hemolysin antibody generation and the like, and the compound pharmaceutical composition with good activity in the aspects of cough relieving, asthma relieving, phlegm eliminating, swelling diminishing, inflammation diminishing, immunity enhancing and the like is obtained.

Detailed Description

The present invention will be described in further detail with reference to examples, but the embodiments of the present invention are not limited thereto.